Engflag

Halovate

Quick links to important sections

Halovate

Halovate_DA

Method of action: Very Strong

Treatment option: Plaque Psoriasis, Psoriasis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Halovate

Quick Facts

Property Description
Active ingredient Ulobetasol Propionate
Form Topical formulation (Ointment, Cream, Lotion, Solution)
Pharmacological class Super-high Potency Corticosteroid (Class I Glucocorticoid)
Common use Symptomatic relief for severe inflammatory dermatoses
Origin Synthetic drug

What Type of Medicine is Halovate?

Halovate is a distinct, prescription-only dermatological agent containing the active compound Ulobetasol Propionate. This medicine is classified as a potent, synthetic glucocorticoid and falls under the broader category of corticosteroids. The compound's synthetic origin results in a precise and highly targeted effect on inflammatory processes in the skin. Halovate is typically reserved for adult and older adolescent patients with specific, severe skin conditions requiring a robust topical intervention.

Halovate’s Potency Class and Formulation

The active ingredient in Halovate, Ulobetasol Propionate, is strictly categorized as a super-high potency corticosteroid, corresponding to Class I—the highest potency ranking within the established topical corticosteroid classification system. This classification is clinically recognized for its strong ability to cause local blood vessel narrowing (vasoconstriction), a key indicator of its intensive anti-inflammatory power. Halovate is available exclusively in various topical formulations, including ointment, cream, lotion, and solution, intended only for direct topical application to the affected skin surface.

General Purpose: How Halovate Helps the Skin

The overall purpose of this medicine is to provide rapid and intensive symptomatic relief from the severe visible signs and discomfort associated with highly inflammatory skin conditions collectively known as dermatoses. The super-high potency of Ulobetasol Propionate drives a powerful local anti-inflammatory action and immunosuppressive action. This action intervenes in the cellular pathways to reduce the release of chemical mediators that cause tissue swelling, redness, and persistent, intense itching (antipruritic action). This powerful and concentrated effect is necessary for localized, severe inflammation that requires substantial, rapid control.

Regulatory References

  1. corticosteroids
  2. highest potency ranking within the established topical corticosteroid classification system

What side effects are possible with Halovate?

Possible Side Effects and Safety Information

Halovate (Ulobetasol Propionate) is a super-high potency topical corticosteroid, and its safety profile is primarily characterized by effects at the application site and the potential for systemic absorption. The severity and classification of adverse reactions are based on official government regulatory documents.

Documented Adverse Reactions

The most frequently reported adverse reactions are localized and typically occur early in treatment. Less common effects relate to changes in skin structure or inflammation.

Classification Examples of Officially Documented Effects
Common (Reported in ge 1% of patients) Burning sensation, stinging sensation
Less Common/Infrequent (Reported in < 1% of patients) Skin atrophy (thinning), telangiectasia (spider veins), pruritus, folliculitis, hypertrichosis, dryness

These effects fall under the regulatory grouping of Skin and Subcutaneous Tissue Disorders.

Systemic and High-Risk Safety Considerations

Due to the medicine's potency, systemic absorption is a documented risk, potentially affecting the Endocrine System. The most serious official safety concern is Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which can lead to adrenal insufficiency. Other serious effects associated with excessive systemic glucocorticoid exposure include manifestations of Cushing’s syndrome and disturbances in glucose regulation (hyperglycemia).

Risk factors for these systemic effects include long-term use, application over large surface areas, or the use of occlusive dressings. Furthermore, pediatric patients are officially noted to be at greater risk for systemic toxicity due to their body surface area-to-weight ratio.

Halovate is contraindicated in individuals with known hypersensitivity to the drug. Its use requires concurrent antimicrobial therapy if an active skin infection is present, and it is not for ophthalmic use.

Overdose and Emergency Response

Overdose and When to Seek Help

Halovate (halobetasol propionate) is a highly potent topical corticosteroid. An acute overdose from excessive or prolonged topical application is generally unlikely to result in immediate severe symptoms. However, using significantly more than the prescribed amount, applying it over a large surface area of the body, or using it for longer than the recommended two-week period increases the risk of systemic absorption into the bloodstream.

Prolonged or high-dose use can lead to serious systemic side effects, primarily related to the suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which is the body's natural stress-response system. This can lead to conditions such as Cushing's syndrome or adrenal insufficiency upon sudden withdrawal.

Signs of Systemic Over-Absorption

Systemic Side Effect Potential Symptoms
Adrenal Insufficiency Severe fatigue, dizziness, nausea, vomiting, or muscle weakness.
Cushing's Syndrome Weight gain (especially in the face, neck, and torso), muscle weakness, easy bruising, or thinning skin.
Other Blurred vision, persistent headache, increased thirst, or increased urination.

When to Seek Medical Attention

If you accidentally swallow Halovate, seek immediate medical attention by calling the Poison Control Center or emergency services. If you experience any signs of systemic over-absorption listed above, or if your skin condition worsens, develops an infection (e.g., redness, swelling, pus), or does not improve within the expected timeframe, consult your healthcare provider promptly.

Therapeutic Uses of Halovate

What Halovate Treats: Main Uses and Benefits

This medication is commonly used to help with the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Halovate is applied in addressing situations involving inflammatory or irritative processes that require additional symptomatic support. It is relevant in conditions involving episodic or fluctuating manifestations, such as severe plaque psoriasis and severe forms of atopic or contact dermatitis, and is relevant when supportive symptom management is appropriate.

The medication helps address symptom clusters related to physical discomfort, specifically targeting intense itching (pruritus), pronounced redness, and swelling that interfere with daily functioning. The symptomatic relief generally helps patients cope more steadily with difficult episodes.

“The primary goal of using this agent is used to help manage severe symptomatic distress and contributes to easing the overall symptom load.”

Quick Fact: Relief for Severe Inflammatory Skin Symptoms

Symptom Domain Relief Provided
Pruritus Helps ease intense and persistent itching.
Inflammation May assist in easing redness and swelling.
Severity Contributes to easing the symptoms of resistant, severe flares.

Eligibility and Restrictions for Use

Halovate (Halobetasol Propionate) is an ultra-high potency topical corticosteroid whose use is subject to specific regulatory limitations and patient eligibility rules.

Eligibility Status Applicable Populations and Conditions
Contraindicated Patients with a known allergy or hypersensitivity to any component of the formulation. Should not be used for rosacea or perioral dermatitis.
Not Recommended Children younger than 12 years of age (safety and efficacy not established). Use on the face, groin, armpits (axillae), or under occlusive dressings. Treatment beyond two consecutive weeks (or eight weeks for specific lotion formulations).
Requires Caution Pregnancy and lactation (use only if benefit outweighs risk; potential for systemic effects). Patients with pre-existing conditions like Cushing's syndrome or diabetes, as the medicine may worsen these conditions or cause HPA axis suppression. Use on broken skin or for skin infections.

The drug is typically approved for use in adults and children 12 years of age and older for certain skin conditions. Due to the high potency of Halobetasol, all patients must adhere strictly to the prescribed duration and application sites to minimize the risk of serious local and systemic side effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Halovate (Ulobetasol Propionate) topical formulations primarily defines interaction risk based on the potential for increased systemic corticosteroid exposure.

Documented Interaction Patterns

The most significant and documented interaction is a pharmacodynamic interaction involving cumulative corticosteroid use.

Category Officially Documented Interaction Outcome/Risk Classification
Interacting Product Class Other corticosteroid-containing products (topical or systemic). Increased total systemic exposure and additive risk of systemic effects.
Mechanism Basis Additive pharmacodynamic effect. Risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and hyperglycemia.

Co-administration with any other corticosteroid-containing medicine is documented to amplify the risk of systemic effects due to the combined dose contributing to the body’s overall steroid load. The official prescribing information does not list explicit interactions involving specific cytochrome P450 enzymes (CYP) or drug transporters for this topical medicine. Therefore, its interaction profile is centered on this cumulative exposure risk, not metabolic interference.

Population-Specific Notes

The risk of systemic exposure-related interactions, such as HPA axis suppression, is officially noted to be heightened in specific patient populations. These include individuals with hepatic impairment (liver failure) and pediatric patients, where the ratio of skin surface area to body mass contributes to a higher rate of absorption. No specific interactions with food, alcohol, or herbal products are officially documented in the available regulatory labeling.

Mechanism of Action

Enzymatic Target and Inhibition

Halovate functions as an inhibitor of farnesyl pyrophosphate (FPP) synthase, an essential enzyme in the mevalonate pathway within osteoclasts.

Intracellular Cascade

By inhibiting FPP synthase, Halovate disrupts the prenylation of small GTPases (such as Rab and Rho). This molecular event prevents the necessary activation and membrane localization of these proteins. The resulting loss of function directly prevents the formation of the ruffled border, which is required for osteoclast adhesion and activity.

Physiological Consequence

The subsequent apoptotic signaling cascades within the osteoclast cell lead to a reduction in osteoclast viability. This cellular outcome alters the ratio between bone formation and bone resorption by suppressing the resorptive activity of osteoclasts, consequently impacting bone mineral density.

Dosage and Administration Information

How Halovate is Used: Official Administration Guidelines

Halovate (Halobetasol Propionate) is administered solely by the topical route directly onto the skin surface. Its use is strictly prohibited for ophthalmic, oral, or intravaginal application. The official instructions for this super-high potency corticosteroid define precise administration parameters to govern exposure and ensure proper use.

Official Usage Protocols

Feature Guideline
Dosing Principle Apply a thin layer to the affected area. The total weekly dosage for 0.05% formulations must not exceed 50 grams.
Frequency Once or twice daily for 0.05% formulations (cream, ointment, foam). The 0.01% lotion is typically applied once daily.
Duration Limit Treatment with 0.05% formulations is restricted to a maximum of two consecutive weeks. The 0.01% lotion may be used for up to eight consecutive weeks. Therapy must be discontinued when control is achieved.
Restricted Areas Application must be avoided on the face, groin, or armpits (axillae).

Administration and Population Rules

To apply the medicine, it must be gently and completely rubbed in. For foam formulations, the container must be shaken well before use. Furthermore, the treated skin area should not be covered with occlusive dressings unless specifically directed.

Regarding patient age, use of the 0.05% formulations is not recommended for children under 12 years of age. The high-level procedural rules are designed to strictly contain the administration pattern, reinforcing the necessary constraints on frequency, quantity, and duration inherent to a super-high potency topical agent.

Recent Clinical Evidence

Evidence Base for Plaque Psoriasis

The primary research for Halovate (Ulobetasol Propionate) research examined its effect in short-term randomized controlled trials (RCTs) against an inactive vehicle in patients with moderate-to-severe plaque psoriasis. Researchers focused on outcomes related to physical discomfort, evaluating high-level changes in disease severity using the Investigator Global Assessment (IGA) score and monitoring specific signs like redness, scaling, and plaque elevation. Findings describe patterns observed in the studies where a greater proportion of participants receiving the active treatment met pre-defined endpoints compared to those receiving the vehicle. This primary research is confined to short-term continuous application, observing responses over defined time intervals of eight weeks or less.

Studies in Other Inflammatory Skin Conditions

Halovate was evaluated in settings involving other corticosteroid-responsive dermatoses, such as atopic dermatitis (eczema). The evidence base for these conditions is limited and heterogeneous compared to the research for plaque psoriasis, often derived from smaller-scale comparative trials. Studies explored various comparisons, often involving the active agent against other topical corticosteroids. Certainty remains low for many of these varied indications, and specific clinical outcomes are not fully established through dedicated pivotal trials.

Long-Term Research and Limitations

Efficacy research primarily involved limited follow-up durations for continuous use. However, long-term open-label studies monitored patient patterns during intermittent, as-needed application for up to one year. These findings help contextualize patient-reported experience. Long-term effects are not fully established regarding consistent skin improvement over time.

A key limitation of the evidence is the lack of comparative evidence against other active high-potency agents. Additionally, the results apply only to the populations studied, which means data are still emerging for individuals with extensive skin involvement. Data for certain groups remain insufficient, especially for the elderly or pregnant individuals.

Key Studies & References

  1. Halobetasol Cream - StatPearls (Overview of Indications and Potency Classification)

How should Halovate be stored and disposed of?

How to Store and Dispose of Halovate? (Halobetasol Propionate)

Official regulatory labeling dictates strict storage and disposal requirements to maintain the product's stability and safety.

Storage Conditions

Requirement Specifics
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze or expose to temperatures above 49 C (120 F) (especially for foam).
Protection Keep the medication in the original, tightly closed container, protected from moisture and direct light.
Flammability The foam formulation is flammable; avoid heat, flame, or smoking during and immediately after use. Do not puncture or incinerate the pressurized can.
Child Safety Keep all forms of this medication strictly out of the reach of children.

Disposal Instructions

Do not dispose of unused or expired Halovate with routine household trash. Consult a healthcare professional or pharmacist for instructions on proper disposal, which is required for certain formulations to be managed as biomedical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Halovate found in:

A-Z Index: